Victoria Jansen, MD
Internal Medicine · Swansea, ILNPI 1932191863
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 297 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 14.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,390 and has fallen 74.8% since, to $351 in 2025. Among internal medicine clinicians in IL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 297 payments — averaging $14.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$634
- Lilly USA, LLC$618
- GSK$428
- Boehringer Ingelheim$428
- Johnson & Johnson$350
- AstraZeneca$307
- plus $2K from 24 others
What the payments were for
- Food & beverage$4,301100%
- Entertainment$160%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 52 | $634 |
| Lilly USA, LLC | 33 | $618 |
| GSK | 34 | $428 |
| Boehringer Ingelheim | 30 | $428 |
| Johnson & Johnson | 27 | $350 |
| AstraZeneca | 18 | $307 |
| Pfizer | 26 | $292 |
| AbbVie(2 entities) | 7 | $128 |
| Amarin Pharma, Inc. | 7 | $120 |
| Merck | 7 | $109 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $99 |
| Novartis | 7 | $95 |
| Amgen | 4 | $76 |
| Bayer | 4 | $62 |
| Sanofi-aventis U.S. LLC | 4 | $59 |
| Sanofi Pasteur Inc. | 3 | $58 |
| E.r. Squibb & Sons, L.L.C. | 4 | $57 |
| Kowa Pharmaceuticals America, Inc. | 4 | $54 |
| Exact Sciences | 3 | $52 |
| Nestle Healthcare Nutrition Inc. | 3 | $41 |
| Astellas Pharma US Inc | 2 | $40 |
| Axsome Therapeutics, Inc. | 2 | $39 |
| Sunovion Pharmaceuticals Inc. | 2 | $36 |
| Sumitomo Pharma America, Inc. | 2 | $32 |
| Dexcom, Inc. | 2 | $32 |
| Optos, Inc. | 1 | $16 |
| Abbott | 1 | $15 |
| Kaleo, Inc. | 1 | $14 |
| Zealand Pharma US, Inc. | 1 | $14 |
| Biohaven Pharmaceuticals, Inc. | 1 | $13 |
How this compares
$4,317 in reported general payments places this provider in the 90th percentile of 5,182 internal medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 150 | $118,938 |
| TrulicityDulaglutide | 44 | $63,389 |
| JardianceEmpagliflozin | 47 | $58,600 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 67 | $47,201 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 61 | $44,007 |
| OzempicSemaglutide | 22 | $38,004 |
| Semglee (Yfgn) PenInsulin Glargine-Yfgn | 45 | $36,192 |
| ProliaDenosumab | 20 | $34,808 |
| CreonLipase/Protease/Amylase | 19 | $34,038 |
| MounjaroTirzepatide | 21 | $32,945 |
| JanuviaSitagliptin Phosphate | 17 | $28,973 |
| XareltoRivaroxaban | 38 | $23,515 |
| RybelsusSemaglutide | 15 | $18,103 |
| TradjentaLinagliptin | 17 | $16,607 |
| EntrestoSacubitril/Valsartan | 12 | $10,546 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $292 | $118,938150 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta, Breo Ellipta | $428 | $103,287153 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $618 | $96,33465 claims |
| Boehringer IngelheimJardiance, Tradjenta | $428 | $75,20864 claims |
| Novo NordiskOzempic, Rybelsus | $634 | $56,10637 claims |
| AmgenProlia | $76 | $34,80820 claims |
| AbbVieCreon | $128 | $34,03819 claims |
| MerckJanuvia | $109 | $28,97317 claims |
| Johnson & JohnsonXarelto | $350 | $23,51538 claims |
| NovartisEntresto | $95 | $10,54612 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $59 | $9,44311 claims |
| AstraZenecaSymbicort | $307 | $6,51114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,182 internal medicine providers in Illinois.
Other internal medicine in Swansea
- Mounir ShenoudaSwansea$62K
- Philip ChuSwansea$36K
- Zaid JabbarOak Brook$1.2M
- Merle DiamondChicago$1.1M
- David ReckerLibertyville$868K
- Yazen JoudehOrland Park$661K
- Robert KushnerChicago$516K
- William CruikshankOak Lawn$431K
- Romeo UrsuaChicago$420K
- Shaina RozellChicago Ridge$366K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.